And a recent PR related to Ampligen and CFS/ME. AIM ImmunoTech Provides Update on Commercial Launch of Ampligen(R) in Argentina for the Treatment...
You'll find this interesting - especially for those who were not around for the AdCom meetings of 2012-13. Maybe it can be used to petition the...
AIM ImmunoTech's Ampligen Receives Clearance from FDA for Exportation to Argentina for the Treatment of Severe Chronic Fatigue Syndrome...
Hemispherx Links Stanford's ME/CFS Diagnostic to a Potential Path Forward for Ampligen Commercialization ... "This is a potentially landmark...
LOTS of coverage. I hope it pans out....
They have 2 cancer trials underway, IRB approval to start the triple negative breast cancer and a planned start to ovarian trial at the end of...
Not to get technical Danny, but the Advisory Committee gave a mostly negative vote in December of 2012, with the FDA declining approval in...
No details are known, I think they are still negotiating (and have been for a long while). My guess would be 300+
I've heard that Peterson is limiting his ampligen patients. The paragraph refers to a future planned trial (to satisfy the FDA, the 2nd...
Indeed. That's always been the problem with the amp-511. Few can afford it.
Merged thread Hemispherx Biopharma Inc. Announces First Large Ampligen Shipment to a Clinical Site for Use in U.S. Expanded Access Program...
Contact hemispherx to find out the status.... GP-Pharm is handling Argentina. http://gp-pharm.com/
That AMP-511 is a compassionate treatment protocol that’s been available for 20 years. FDA wants one more large trial. Argentina has approved.
Yes, by IV. It’s a large molecule drug, so it’s doubtful that will ever change.
From today's PR: In parallel, we continue to pursue Ampligen for the treatment of severe myalgic encephalomyelitis/chronic fatigue syndrome...
Hemispherx Opens FDA-Approved Reimbursement Based Expanded Access Treatment Program for ME/CFS to New Enrollees at Approved Clinical Sites in...
cGMP = Current Good Manufacturing Practices
Hemispherx Comments on $500+ Million Market Opportunity for Ampligen®, the Only Late Stage ME/CFS Candidate in the U.S. . . . Dr. Daniel Peterson,...
Here is a workshop announcement Link: http://solvecfs.org/fda-drug-development-workshop-dates-announced/ (The Federal Register link no longer...
Excellent letter by Hemispherx CEO. Filed with the SEC https://www.sec.gov/Archives/edgar/data/946644/000149315218000820/ex99-1.htm January 22,...
Separate names with a comma.
